Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).
MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022. The company handles research, clinical development, sales, marketing, medical affairs, and business development functions. MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.
The Director, Medical Science MSES, will be primarily responsible for creating plans for early clinical development and implementing Early Development plans that are aligned with company’s disease and pathway strategies. The successful candidate will be responsible for shaping the overall plans for programs and in creating and implementing experimental medicine studies.
Reporting into the Senior Director of the Medical Science Early-Stage, the Director, MSES will lead clinical and scientific aspects of Early Development studies from Phase 0 through Proof-of-Concept studies. In this role, the Director, MSES, will contribute to accelerating the company’s pipeline from portfolio entry to Proof-of-Concept (PoC). The Director, MSES, should have expertise in one or more of the MSES areas: early-stage clinical development, biomarker development, precision medicine, and disease biology research.
The Medical Science Early-Stage group of Early Clinical Development serves as a pivotal bridge between Discovery/Early Development Research and the later phase Clinical Development group. It provides the necessary scientific and clinical expertise to advance an industry-leading pipeline of novel mechanism small molecules and biologic agents to address unmet need in immunology, neurology, and other rare diseases. This position will play a ‘dual role’, contributing both scientific and early clinical development expertise.